Global Particle Therapy Market By Type, By Offerings, By Cancer Type, By End Users: Global Insights & Analysis Report (2015 – 2031)

  • Industry: Healthcare
  • Report ID: TNR-110-1020
  • Number of Pages: 420
  • Table/Charts : Yes
  • November, 2023
  • Base Year : 2024
  • No. of Companies : 10+
  • No. of Countries : 29
  • Views : 10054
  • Covid Impact Covered: Yes
  • War Impact Covered: Yes
  • Formats : PDF, Excel, PPT

Global Particle Therapy Market Crossed the Mark of US$ 680 Mn in 2022, Anticipated to Reach CAGR of 8.6% from 2023-2031.

Particle therapy, also known as particle beam therapy or particle radiation therapy, is an advanced form of cancer treatment that uses charged particles, such as protons or carbon ions, to irradiate and destroy cancer cells. Unlike conventional radiation therapy, which uses X-rays or photons, particle therapy harnesses the unique properties of charged particles to deliver highly targeted and precise doses of radiation to cancerous tumors.

The global particle therapy market is experiencing robust growth driven by increasing awareness of its benefits, advancements in technology, and a rising incidence of cancer worldwide. Particle therapy, including proton therapy and carbon ion therapy, has gained prominence as an effective and precise cancer treatment option with reduced side effects compared to conventional radiation therapy.

Global Particle Therapy Market Revenue & Forecast, (US$ Million), 2015 – 2031

Global Particle Therapy Market Growth Drivers

  • Increasing Cancer Incidence: The rising global incidence of cancer continues to be a significant driver for the particle therapy market. In 2022, breast cancer and lung cancer stood out as the two most prevalent cancer types globally, accounting for 14.5% and 14.2% of all newly diagnosed cases. The United States reported approximately 1.9 million new cancer cases and 609,360 cancer-related deaths in the same year. As the number of cancer cases grows, there is a greater demand for advanced and precise cancer treatment options like particle therapy.
  • Precision and Reduced Side Effects: Particle therapy offers superior precision in targeting cancer cells while minimizing damage to healthy tissues compared to conventional radiation therapy. This advantage drives patient demand and adoption of the particle therapy market.
  • Pediatric Cancer Treatment: Particle therapy is especially valuable in treating pediatric cancers, where minimizing radiation exposure to healthy tissues is crucial. The growing awareness of this benefit has increased the use of particle therapy in pediatric oncology.
  • Technological Advancements: Ongoing advancements in particle therapy technology, including improved particle accelerators and treatment planning systems, enhance treatment effectiveness and reduce costs.
  • Government Support and Funding: Government support and funding for research, development, and the establishment of particle therapy centers contribute to particle therapy market growth. Public investments help expand access to particle therapy in various regions.
  • Insurance Coverage: As more insurance providers cover particle therapy treatments, it becomes more accessible to a broader patient population. This financial support further drives adoption.

Global Particle Therapy Market Restraints

  • High Initial Costs: Setting up a particle therapy facility requires a substantial initial investment, including the construction of specialized treatment centers and the purchase of expensive equipment. This cost can be a significant barrier for the particle therapy market.
  • Limited Accessibility: Particle therapy centers are not available in all regions, leading to limited accessibility for patients. Geographic disparities in access remain a challenge.
  • Reimbursement Challenges: Reimbursement policies and processes can be complex, leading to delays and uncertainties for both patients and healthcare providers. Overcoming reimbursement challenges is crucial for particle therapy market growth.
  • Competition from Conventional Radiation Therapy: Conventional radiation therapy using X-rays remains the standard of care in many places due to its lower cost and wider availability. Particle therapy faces competition from established radiation treatments.

Proton therapy has gained attention and captured a significant share in the particle therapy market in 2022 for several reasons:

  • Precision and Targeting: Proton therapy is highly precise in delivering radiation to tumors. It allows for better targeting of cancer cells while minimizing damage to nearby healthy tissues and organs. This precision is especially beneficial in treating pediatric cancers and tumors located near critical structures.
  • Reduced Side Effects: Due to its precise targeting, proton therapy often results in fewer short-term and long-term side effects compared to traditional radiation therapy. This can lead to a better quality of life for cancer patients post-treatment.
  • Clinical Efficacy: Proton therapy has demonstrated clinical efficacy in treating various types of cancers, including brain tumors, prostate cancer, head and neck cancers, and certain pediatric cancers. Its effectiveness in treating specific tumor types has contributed to its adoption.

As awareness of proton therapy has grown among patients and healthcare professionals, there has been an increasing demand for this treatment option. Patients often seek out proton therapy centers for its potential benefits, boosting its share in the particle therapy market.

Cyclotrons are an essential component of the particle therapy market accounting for ~74.8% of the total market share in 2022, particularly in the context of proton therapy. Cyclotrons are a key technology for generating the proton beams needed for proton therapy. They accelerate protons to the necessary high energies, making them suitable for precise cancer treatment. Proton therapy has gained popularity for its ability to target tumors with high precision while sparing healthy tissues. Cyclotrons are integral to the delivery of this treatment, making them a central component in proton therapy centers. Ongoing research and development efforts have focused on improving cyclotron technology to make it more efficient, compact, and cost-effective. This has contributed to the continued adoption of proton therapy. Competition in this sector has driven innovation and influenced market dynamics. To gain a competitive edge in the particle therapy market, companies are continuously investing in research and development to improve cyclotron technology. They strive to make cyclotrons more efficient, compact, and cost-effective. This results in the development of advanced models with better performance characteristics.

For example, companies like IBA (Ion Beam Applications) and Varian (now part of Siemens Healthineers) have introduced innovative cyclotron designs for proton therapy that are more energy-efficient and compact, making them easier to install in healthcare facilities.

Competition encourages companies to diversify their product offerings to cater to different market segments. For instance, companies are developing cyclotrons with varying energy levels to meet the needs of different proton therapy applications. This diversification enables healthcare providers to choose the equipment that best fits their clinical requirements. For example, Cyclotron Radioisotope Products (CRP) offers cyclotrons with various energy levels for both research and clinical applications.

Competitive Landscape

Some of the players operating in the global particle therapy market are

  • DANFYSIK A/S
  • Elekta AB
  • Hitachi, Ltd
  • IBA SA
  • Mevion Medical Systems
  • Mitsubishi Electric Corporation
  • P-Cure
  • ProTom International
  • Provision Healthcare
  • Sumitomo Heavy Industries Ltd.
  • Varian Medical Systems, Inc.
  • Other Industry Participants

Global Particle Therapy Market Report Coverage

Report Specifications Details
Market Revenue in 2022 US$ 680 Million
Market Size Forecast by 2031 US$ 1345.39 Million
Growth Rate (CAGR) 8.6%
Historic Data 2015 – 2021
Base Year for Estimation 2022
Forecast Period 2023 – 2031
Report Inclusions Market Size & Estimates, Market Dynamics, Competitive Scenario, Trends, Growth Factors, Market Determinants, Key Investment Segmentation, Product/Service/Solutions Benchmarking
Segments Covered By Type, By Offerings, By Cancer Type, By End Users
Regions Covered North America, Europe, Asia Pacific, Middle East & Africa, Latin America
Countries Covered U.S., Canada, Mexico, Rest of North America,  France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe,  China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific,  Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa,  Brazil, Argentina, Rest of Latin America
Key Players DANFYSIK A/S, Elekta AB, Hitachi, Ltd, IBA SA, Mevion Medical Systems, Mitsubishi Electric Corporation, P-Cure, ProTom International, Provision Healthcare, Sumitomo Heavy Industries Ltd., Varian Medical Systems, Inc., Other Industry Participants
Customization Scope Customization allows for the inclusion/modification of content pertaining to geographical regions, countries, and specific market segments.
Pricing & Procurement Options Explore purchase options tailored to your specific research requirements
Contact Details Consult With Our Expert

Japan (Toll-Free): – +81 663-386-8111

South Korea (Toll-Free): – +82-808- 703-126

Saudi Arabia (Toll-Free): – +966 800 850 1643

United States: +1 302-232-5106

United Kingdom: +447537105080

E-mail:  askanexpert@thenicheresearh.com

 

 

Global Particle Therapy Market:

By Type

  • Proton Therapy
    • Single room
    • Multi room
    • Expandable rooms
  • Carbon ion Therapy
    • Fixed beam treatment room
    • Rotating gantry treatment room
  • Hybrid

By Offerings

  • Products
    • Cyclotron
    • Synchrotons
  • Services

By Cancer Type

  • Brain tumors
  • Spinal cord tumors
  • Head and neck cancer
  • Breast cancer
  • Metastatic tumors
  • Liver cancer
  • Pancreatic cancer
  • Rectal cancer
  • Gynecological tumors
  • Bone and Soft tissue Tumors
  • Pediatric Cancer
  • Intraocular tumors
  • Lung Cancer
  • Esophageal cancer
  • Kidney cancer
  • Prostate cancer
  • Bladder cancer
  • Others

By End Users

  • Hospitals
  • Cancer Treatment Centers
  • Research Laboratories
  • Others

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)

Report Coverage and Deliverables: LINK

 

Table of Contents

.

1.Market Scope
1.1.Market Segmentation
1.2.Years Considered
1.2.1.Historic Years: 2015 - 2021
1.2.2.Base Year: 2022
1.2.3.Forecast Years: 2023 – 2031
2.Key Target Audiences
3.Research Methodology
3.1.Primary Research
3.1.1.Research Questionnaire
3.1.2.Global Percentage Breakdown
3.1.3.Primary Interviews: Key Opinion Leaders (KOLs)
3.2.Secondary Research
3.2.1.Paid Databases
3.2.2.Secondary Sources
3.3.Market Size Estimates
3.3.1.Top-Down Approach
3.3.2.Bottom-Up Approach
3.4.Data Triangulation Methodology
3.5.Research Assumptions
4.Recommendations and Insights from TNR’s Perspective**
5.Holistic Overview of Particle Therapy Market
6.Market Synopsis: Particle Therapy Market
7.Particle Therapy Market Analysis: Qualitative Perspective
7.1.Introduction
7.1.1.Product Definition
7.1.2.Industry Development
7.2.Market Dynamics
7.2.1.Drivers
7.2.2.Restraints
7.2.3.Opportunities
7.3.Trends in Particle Therapy Market
7.4.Market Determinants Radar Chart
7.5.Macro-Economic and Micro-Economic Indicators: Particle Therapy Market
7.6.Porter’s Five Force Analysis
8.Global Particle Therapy Market Analysis and Forecasts, 2023 – 2031
8.1.Overview
8.1.1.Global Particle Therapy Market Revenue (US$ Mn)
8.2.Global Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
8.2.1.Proton Therapy (Definition, Market Estimation and Penetration, 2015 - 2022, Market Estimation (2015 - 2022), Market Forecast (2023 – 2031), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Single room, Multi room , Expandable room)
8.2.1.1.Single room
8.2.1.2.Multi room
8.2.1.3.Expandable room
8.2.2.Carbon ion Therapy (Definition, Market Estimation and Penetration, 2015 - 2022, Market Estimation (2015 - 2022), Market Forecast (2023 – 2031), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Fixed beam treatment room , Rotating gantry treatment room)
8.2.2.1.Fixed beam treatment room
8.2.2.2.Rotating gantry treatment room
8.2.3.Hybrid Therapy
8.2.3.1.Definition
8.2.3.2.Market Estimation and Penetration, 2015 - 2022
8.2.3.3.Market Forecast, 2023 - 2031
8.2.3.4.Compound Annual Growth Rate (CAGR)
8.2.3.5.Regional Bifurcation
8.2.3.5.1.North America
8.2.3.5.1.1.Market Estimation, 2015 - 2022
8.2.3.5.1.2.Market Forecast, 2023 - 2031
8.2.3.5.2.Europe
8.2.3.5.2.1.Market Estimation, 2015 - 2022
8.2.3.5.2.2.Market Forecast, 2023 - 2031
8.2.3.5.3.Asia Pacific
8.2.3.5.3.1.Market Estimation, 2015 - 2022
8.2.3.5.3.2.Market Forecast, 2023 - 2031
8.2.3.5.4.Middle East and Africa
8.2.3.5.4.1.Market Estimation, 2015 - 2022
8.2.3.5.4.2.Market Forecast, 2023 - 2031
8.2.3.5.5.Latin America
8.2.3.5.5.1.Market Estimation, 2015 - 2022
8.2.3.5.5.2.Market Forecast, 2023 - 2031
8.3.Key Segment for Channeling Investments
8.3.1.By Type
9.Global Particle Therapy Market Analysis and Forecasts, 2023 – 2031
9.1.Overview
9.2.Global Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
9.2.1.Products (Definition, Market Estimation and Penetration, 2015 - 2022, Market Estimation (2015 - 2022), Market Forecast (2023 – 2031), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Cyclotron, Synchrotrons)
9.2.1.1.Cyclotron
9.2.1.2.Synchrotrons
9.2.2.Services
9.2.2.1.Definition
9.2.2.2.Market Estimation and Penetration, 2015 - 2022
9.2.2.3.Market Forecast, 2023 - 2031
9.2.2.4.Compound Annual Growth Rate (CAGR)
9.2.2.5.Regional Bifurcation
9.2.2.5.1.North America
9.2.2.5.1.1.Market Estimation, 2015 - 2022
9.2.2.5.1.2.Market Forecast, 2023 - 2031
9.2.2.5.2.Europe
9.2.2.5.2.1.Market Estimation, 2015 - 2022
9.2.2.5.2.2.Market Forecast, 2023 - 2031
9.2.2.5.3.Asia Pacific
9.2.2.5.3.1.Market Estimation, 2015 - 2022
9.2.2.5.3.2.Market Forecast, 2023 - 2031
9.2.2.5.4.Middle East and Africa
9.2.2.5.4.1.Market Estimation, 2015 - 2022
9.2.2.5.4.2.Market Forecast, 2023 - 2031
9.2.2.5.5.Latin America
9.2.2.5.5.1.Market Estimation, 2015 - 2022
9.2.2.5.5.2.Market Forecast, 2023 - 2031
9.3.Key Segment for Channeling Investments
9.3.1.By Offerings
10.Global Particle Therapy Market Analysis and Forecasts, 2023 – 2031
10.1.Overview
10.2.Global Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
10.2.1.Brain tumors
10.2.1.1.Definition
10.2.1.2.Market Estimation and Penetration, 2015 - 2022
10.2.1.3.Market Forecast, 2023 - 2031
10.2.1.4.Compound Annual Growth Rate (CAGR)
10.2.1.5.Regional Bifurcation
10.2.1.5.1.North America
10.2.1.5.1.1.Market Estimation, 2015 - 2022
10.2.1.5.1.2.Market Forecast, 2023 - 2031
10.2.1.5.2.Europe
10.2.1.5.2.1.Market Estimation, 2015 - 2022
10.2.1.5.2.2.Market Forecast, 2023 - 2031
10.2.1.5.3.Asia Pacific
10.2.1.5.3.1.Market Estimation, 2015 - 2022
10.2.1.5.3.2.Market Forecast, 2023 - 2031
10.2.1.5.4.Middle East and Africa
10.2.1.5.4.1.Market Estimation, 2015 - 2022
10.2.1.5.4.2.Market Forecast, 2023 - 2031
10.2.1.5.5.Latin America
10.2.1.5.5.1.Market Estimation, 2015 - 2022
10.2.1.5.5.2.Market Forecast, 2023 - 2031
10.2.2.Spinal cord tumors
10.2.2.1.Definition
10.2.2.2.Market Estimation and Penetration, 2015 - 2022
10.2.2.3.Market Forecast, 2023 - 2031
10.2.2.4.Compound Annual Growth Rate (CAGR)
10.2.2.5.Regional Bifurcation
10.2.2.5.1.North America
10.2.2.5.1.1.Market Estimation, 2015 - 2022
10.2.2.5.1.2.Market Forecast, 2023 - 2031
10.2.2.5.2.Europe
10.2.2.5.2.1.Market Estimation, 2015 - 2022
10.2.2.5.2.2.Market Forecast, 2023 - 2031
10.2.2.5.3.Asia Pacific
10.2.2.5.3.1.Market Estimation, 2015 - 2022
10.2.2.5.3.2.Market Forecast, 2023 - 2031
10.2.2.5.4.Middle East and Africa
10.2.2.5.4.1.Market Estimation, 2015 - 2022
10.2.2.5.4.2.Market Forecast, 2023 - 2031
10.2.2.5.5.Latin America
10.2.2.5.5.1.Market Estimation, 2015 - 2022
10.2.2.5.5.2.Market Forecast, 2023 - 2031
10.2.3.Head and neck cancer
10.2.3.1.Definition
10.2.3.2.Market Estimation and Penetration, 2015 - 2022
10.2.3.3.Market Forecast, 2023 - 2031
10.2.3.4.Compound Annual Growth Rate (CAGR)
10.2.3.5.Regional Bifurcation
10.2.3.5.1.North America
10.2.3.5.1.1.Market Estimation, 2015 - 2022
10.2.3.5.1.2.Market Forecast, 2023 - 2031
10.2.3.5.2.Europe
10.2.3.5.2.1.Market Estimation, 2015 - 2022
10.2.3.5.2.2.Market Forecast, 2023 - 2031
10.2.3.5.3.Asia Pacific
10.2.3.5.3.1.Market Estimation, 2015 - 2022
10.2.3.5.3.2.Market Forecast, 2023 - 2031
10.2.3.5.4.Middle East and Africa
10.2.3.5.4.1.Market Estimation, 2015 - 2022
10.2.3.5.4.2.Market Forecast, 2023 - 2031
10.2.3.5.5.Latin America
10.2.3.5.5.1.Market Estimation, 2015 - 2022
10.2.3.5.5.2.Market Forecast, 2023 - 2031
10.2.4.Breast cancer
10.2.4.1.Definition
10.2.4.2.Market Estimation and Penetration, 2015 - 2022
10.2.4.3.Market Forecast, 2023 - 2031
10.2.4.4.Compound Annual Growth Rate (CAGR)
10.2.4.5.Regional Bifurcation
10.2.4.5.1.North America
10.2.4.5.1.1.Market Estimation, 2015 - 2022
10.2.4.5.1.2.Market Forecast, 2023 - 2031
10.2.4.5.2.Europe
10.2.4.5.2.1.Market Estimation, 2015 - 2022
10.2.4.5.2.2.Market Forecast, 2023 - 2031
10.2.4.5.3.Asia Pacific
10.2.4.5.3.1.Market Estimation, 2015 - 2022
10.2.4.5.3.2.Market Forecast, 2023 - 2031
10.2.4.5.4.Middle East and Africa
10.2.4.5.4.1.Market Estimation, 2015 - 2022
10.2.4.5.4.2.Market Forecast, 2023 - 2031
10.2.4.5.5.Latin America
10.2.4.5.5.1.Market Estimation, 2015 - 2022
10.2.4.5.5.2.Market Forecast, 2023 - 2031
10.2.5.Metastatic tumors
10.2.5.1.Definition
10.2.5.2.Market Estimation and Penetration, 2015 - 2022
10.2.5.3.Market Forecast, 2023 - 2031
10.2.5.4.Compound Annual Growth Rate (CAGR)
10.2.5.5.Regional Bifurcation
10.2.5.5.1.North America
10.2.5.5.1.1.Market Estimation, 2015 - 2022
10.2.5.5.1.2.Market Forecast, 2023 - 2031
10.2.5.5.2.Europe
10.2.5.5.2.1.Market Estimation, 2015 - 2022
10.2.5.5.2.2.Market Forecast, 2023 - 2031
10.2.5.5.3.Asia Pacific
10.2.5.5.3.1.Market Estimation, 2015 - 2022
10.2.5.5.3.2.Market Forecast, 2023 - 2031
10.2.5.5.4.Middle East and Africa
10.2.5.5.4.1.Market Estimation, 2015 - 2022
10.2.5.5.4.2.Market Forecast, 2023 - 2031
10.2.5.5.5.Latin America
10.2.5.5.5.1.Market Estimation, 2015 - 2022
10.2.5.5.5.2.Market Forecast, 2023 - 2031
10.2.6.Liver cancer
10.2.6.1.Definition
10.2.6.2.Market Estimation and Penetration, 2015 - 2022
10.2.6.3.Market Forecast, 2023 - 2031
10.2.6.4.Compound Annual Growth Rate (CAGR)
10.2.6.5.Regional Bifurcation
10.2.6.5.1.North America
10.2.6.5.1.1.Market Estimation, 2015 - 2022
10.2.6.5.1.2.Market Forecast, 2023 - 2031
10.2.6.5.2.Europe
10.2.6.5.2.1.Market Estimation, 2015 - 2022
10.2.6.5.2.2.Market Forecast, 2023 - 2031
10.2.6.5.3.Asia Pacific
10.2.6.5.3.1.Market Estimation, 2015 - 2022
10.2.6.5.3.2.Market Forecast, 2023 - 2031
10.2.6.5.4.Middle East and Africa
10.2.6.5.4.1.Market Estimation, 2015 - 2022
10.2.6.5.4.2.Market Forecast, 2023 - 2031
10.2.6.5.5.Latin America
10.2.6.5.5.1.Market Estimation, 2015 - 2022
10.2.6.5.5.2.Market Forecast, 2023 - 2031
10.2.7.Pancreatic cancer
10.2.7.1.Definition
10.2.7.2.Market Estimation and Penetration, 2015 - 2022
10.2.7.3.Market Forecast, 2023 - 2031
10.2.7.4.Compound Annual Growth Rate (CAGR)
10.2.7.5.Regional Bifurcation
10.2.7.5.1.North America
10.2.7.5.1.1.Market Estimation, 2015 - 2022
10.2.7.5.1.2.Market Forecast, 2023 - 2031
10.2.7.5.2.Europe
10.2.7.5.2.1.Market Estimation, 2015 - 2022
10.2.7.5.2.2.Market Forecast, 2023 - 2031
10.2.7.5.3.Asia Pacific
10.2.7.5.3.1.Market Estimation, 2015 - 2022
10.2.7.5.3.2.Market Forecast, 2023 - 2031
10.2.7.5.4.Middle East and Africa
10.2.7.5.4.1.Market Estimation, 2015 - 2022
10.2.7.5.4.2.Market Forecast, 2023 - 2031
10.2.7.5.5.Latin America
10.2.7.5.5.1.Market Estimation, 2015 - 2022
10.2.7.5.5.2.Market Forecast, 2023 - 2031
10.2.8.Rectal cancer
10.2.8.1.Definition
10.2.8.2.Market Estimation and Penetration, 2015 - 2022
10.2.8.3.Market Forecast, 2023 - 2031
10.2.8.4.Compound Annual Growth Rate (CAGR)
10.2.8.5.Regional Bifurcation
10.2.8.5.1.North America
10.2.8.5.1.1.Market Estimation, 2015 - 2022
10.2.8.5.1.2.Market Forecast, 2023 - 2031
10.2.8.5.2.Europe
10.2.8.5.2.1.Market Estimation, 2015 - 2022
10.2.8.5.2.2.Market Forecast, 2023 - 2031
10.2.8.5.3.Asia Pacific
10.2.8.5.3.1.Market Estimation, 2015 - 2022
10.2.8.5.3.2.Market Forecast, 2023 - 2031
10.2.8.5.4.Middle East and Africa
10.2.8.5.4.1.Market Estimation, 2015 - 2022
10.2.8.5.4.2.Market Forecast, 2023 - 2031
10.2.8.5.5.Latin America
10.2.8.5.5.1.Market Estimation, 2015 - 2022
10.2.8.5.5.2.Market Forecast, 2023 - 2031
10.2.9.Gynecological tumors
10.2.9.1.Definition
10.2.9.2.Market Estimation and Penetration, 2015 - 2022
10.2.9.3.Market Forecast, 2023 - 2031
10.2.9.4.Compound Annual Growth Rate (CAGR)
10.2.9.5.Regional Bifurcation
10.2.9.5.1.North America
10.2.9.5.1.1.Market Estimation, 2015 - 2022
10.2.9.5.1.2.Market Forecast, 2023 - 2031
10.2.9.5.2.Europe
10.2.9.5.2.1.Market Estimation, 2015 - 2022
10.2.9.5.2.2.Market Forecast, 2023 - 2031
10.2.9.5.3.Asia Pacific
10.2.9.5.3.1.Market Estimation, 2015 - 2022
10.2.9.5.3.2.Market Forecast, 2023 - 2031
10.2.9.5.4.Middle East and Africa
10.2.9.5.4.1.Market Estimation, 2015 - 2022
10.2.9.5.4.2.Market Forecast, 2023 - 2031
10.2.9.5.5.Latin America
10.2.9.5.5.1.Market Estimation, 2015 - 2022
10.2.9.5.5.2.Market Forecast, 2023 - 2031
10.2.10.Bone and Soft tissue tumors
10.2.10.1.Definition
10.2.10.2.Market Estimation and Penetration, 2015 - 2022
10.2.10.3.Market Forecast, 2023 - 2031
10.2.10.4.Compound Annual Growth Rate (CAGR)
10.2.10.5.Regional Bifurcation
10.2.10.5.1.North America
10.2.10.5.1.1.Market Estimation, 2015 - 2022
10.2.10.5.1.2.Market Forecast, 2023 - 2031
10.2.10.5.2.Europe
10.2.10.5.2.1.Market Estimation, 2015 - 2022
10.2.10.5.2.2.Market Forecast, 2023 - 2031
10.2.10.5.3.Asia Pacific
10.2.10.5.3.1.Market Estimation, 2015 - 2022
10.2.10.5.3.2.Market Forecast, 2023 - 2031
10.2.10.5.4.Middle East and Africa
10.2.10.5.4.1.Market Estimation, 2015 - 2022
10.2.10.5.4.2.Market Forecast, 2023 - 2031
10.2.10.5.5.Latin America
10.2.10.5.5.1.Market Estimation, 2015 - 2022
10.2.10.5.5.2.Market Forecast, 2023 - 2031
10.2.11.Pediatric cancer
10.2.11.1.Definition
10.2.11.2.Market Estimation and Penetration, 2015 - 2022
10.2.11.3.Market Forecast, 2023 - 2031
10.2.11.4.Compound Annual Growth Rate (CAGR)
10.2.11.5.Regional Bifurcation
10.2.11.5.1.North America
10.2.11.5.1.1.Market Estimation, 2015 - 2022
10.2.11.5.1.2.Market Forecast, 2023 - 2031
10.2.11.5.2.Europe
10.2.11.5.2.1.Market Estimation, 2015 - 2022
10.2.11.5.2.2.Market Forecast, 2023 - 2031
10.2.11.5.3.Asia Pacific
10.2.11.5.3.1.Market Estimation, 2015 - 2022
10.2.11.5.3.2.Market Forecast, 2023 - 2031
10.2.11.5.4.Middle East and Africa
10.2.11.5.4.1.Market Estimation, 2015 - 2022
10.2.11.5.4.2.Market Forecast, 2023 - 2031
10.2.11.5.5.Latin America
10.2.11.5.5.1.Market Estimation, 2015 - 2022
10.2.11.5.5.2.Market Forecast, 2023 - 2031
10.2.12.Intraocular tumors
10.2.12.1.Definition
10.2.12.2.Market Estimation and Penetration, 2015 - 2022
10.2.12.3.Market Forecast, 2023 - 2031
10.2.12.4.Compound Annual Growth Rate (CAGR)
10.2.12.5.Regional Bifurcation
10.2.12.5.1.North America
10.2.12.5.1.1.Market Estimation, 2015 - 2022
10.2.12.5.1.2.Market Forecast, 2023 - 2031
10.2.12.5.2.Europe
10.2.12.5.2.1.Market Estimation, 2015 - 2022
10.2.12.5.2.2.Market Forecast, 2023 - 2031
10.2.12.5.3.Asia Pacific
10.2.12.5.3.1.Market Estimation, 2015 - 2022
10.2.12.5.3.2.Market Forecast, 2023 - 2031
10.2.12.5.4.Middle East and Africa
10.2.12.5.4.1.Market Estimation, 2015 - 2022
10.2.12.5.4.2.Market Forecast, 2023 - 2031
10.2.12.5.5.Latin America
10.2.12.5.5.1.Market Estimation, 2015 - 2022
10.2.12.5.5.2.Market Forecast, 2023 - 2031
10.2.13.Lung cancer
10.2.13.1.Definition
10.2.13.2.Market Estimation and Penetration, 2015 - 2022
10.2.13.3.Market Forecast, 2023 - 2031
10.2.13.4.Compound Annual Growth Rate (CAGR)
10.2.13.5.Regional Bifurcation
10.2.13.5.1.North America
10.2.13.5.1.1.Market Estimation, 2015 - 2022
10.2.13.5.1.2.Market Forecast, 2023 - 2031
10.2.13.5.2.Europe
10.2.13.5.2.1.Market Estimation, 2015 - 2022
10.2.13.5.2.2.Market Forecast, 2023 - 2031
10.2.13.5.3.Asia Pacific
10.2.13.5.3.1.Market Estimation, 2015 - 2022
10.2.13.5.3.2.Market Forecast, 2023 - 2031
10.2.13.5.4.Middle East and Africa
10.2.13.5.4.1.Market Estimation, 2015 - 2022
10.2.13.5.4.2.Market Forecast, 2023 - 2031
10.2.13.5.5.Latin America
10.2.13.5.5.1.Market Estimation, 2015 - 2022
10.2.13.5.5.2.Market Forecast, 2023 - 2031
10.2.14.Esophageal cancer
10.2.14.1.Definition
10.2.14.2.Market Estimation and Penetration, 2015 - 2022
10.2.14.3.Market Forecast, 2023 - 2031
10.2.14.4.Compound Annual Growth Rate (CAGR)
10.2.14.5.Regional Bifurcation
10.2.14.5.1.North America
10.2.14.5.1.1.Market Estimation, 2015 - 2022
10.2.14.5.1.2.Market Forecast, 2023 - 2031
10.2.14.5.2.Europe
10.2.14.5.2.1.Market Estimation, 2015 - 2022
10.2.14.5.2.2.Market Forecast, 2023 - 2031
10.2.14.5.3.Asia Pacific
10.2.14.5.3.1.Market Estimation, 2015 - 2022
10.2.14.5.3.2.Market Forecast, 2023 - 2031
10.2.14.5.4.Middle East and Africa
10.2.14.5.4.1.Market Estimation, 2015 - 2022
10.2.14.5.4.2.Market Forecast, 2023 - 2031
10.2.14.5.5.Latin America
10.2.14.5.5.1.Market Estimation, 2015 - 2022
10.2.14.5.5.2.Market Forecast, 2023 - 2031
10.2.15.Kidney cancer
10.2.15.1.Definition
10.2.15.2.Market Estimation and Penetration, 2015 - 2022
10.2.15.3.Market Forecast, 2023 - 2031
10.2.15.4.Compound Annual Growth Rate (CAGR)
10.2.15.5.Regional Bifurcation
10.2.15.5.1.North America
10.2.15.5.1.1.Market Estimation, 2015 - 2022
10.2.15.5.1.2.Market Forecast, 2023 - 2031
10.2.15.5.2.Europe
10.2.15.5.2.1.Market Estimation, 2015 - 2022
10.2.15.5.2.2.Market Forecast, 2023 - 2031
10.2.15.5.3.Asia Pacific
10.2.15.5.3.1.Market Estimation, 2015 - 2022
10.2.15.5.3.2.Market Forecast, 2023 - 2031
10.2.15.5.4.Middle East and Africa
10.2.15.5.4.1.Market Estimation, 2015 - 2022
10.2.15.5.4.2.Market Forecast, 2023 - 2031
10.2.15.5.5.Latin America
10.2.15.5.5.1.Market Estimation, 2015 - 2022
10.2.15.5.5.2.Market Forecast, 2023 - 2031
10.2.16.Prostate cancer
10.2.16.1.Definition
10.2.16.2.Market Estimation and Penetration, 2015 - 2022
10.2.16.3.Market Forecast, 2023 - 2031
10.2.16.4.Compound Annual Growth Rate (CAGR)
10.2.16.5.Regional Bifurcation
10.2.16.5.1.North America
10.2.16.5.1.1.Market Estimation, 2015 - 2022
10.2.16.5.1.2.Market Forecast, 2023 - 2031
10.2.16.5.2.Europe
10.2.16.5.2.1.Market Estimation, 2015 - 2022
10.2.16.5.2.2.Market Forecast, 2023 - 2031
10.2.16.5.3.Asia Pacific
10.2.16.5.3.1.Market Estimation, 2015 - 2022
10.2.16.5.3.2.Market Forecast, 2023 - 2031
10.2.16.5.4.Middle East and Africa
10.2.16.5.4.1.Market Estimation, 2015 - 2022
10.2.16.5.4.2.Market Forecast, 2023 - 2031
10.2.16.5.5.Latin America
10.2.16.5.5.1.Market Estimation, 2015 - 2022
10.2.16.5.5.2.Market Forecast, 2023 - 2031
10.2.17.Bladder cancer
10.2.17.1.Definition
10.2.17.2.Market Estimation and Penetration, 2015 - 2022
10.2.17.3.Market Forecast, 2023 - 2031
10.2.17.4.Compound Annual Growth Rate (CAGR)
10.2.17.5.Regional Bifurcation
10.2.17.5.1.North America
10.2.17.5.1.1.Market Estimation, 2015 - 2022
10.2.17.5.1.2.Market Forecast, 2023 - 2031
10.2.17.5.2.Europe
10.2.17.5.2.1.Market Estimation, 2015 - 2022
10.2.17.5.2.2.Market Forecast, 2023 - 2031
10.2.17.5.3.Asia Pacific
10.2.17.5.3.1.Market Estimation, 2015 - 2022
10.2.17.5.3.2.Market Forecast, 2023 - 2031
10.2.17.5.4.Middle East and Africa
10.2.17.5.4.1.Market Estimation, 2015 - 2022
10.2.17.5.4.2.Market Forecast, 2023 - 2031
10.2.17.5.5.Latin America
10.2.17.5.5.1.Market Estimation, 2015 - 2022
10.2.17.5.5.2.Market Forecast, 2023 - 2031
10.2.18.Others
10.2.18.1.Definition
10.2.18.2.Market Estimation and Penetration, 2015 - 2022
10.2.18.3.Market Forecast, 2023 - 2031
10.2.18.4.Compound Annual Growth Rate (CAGR)
10.2.18.5.Regional Bifurcation
10.2.18.5.1.North America
10.2.18.5.1.1.Market Estimation, 2015 - 2022
10.2.18.5.1.2.Market Forecast, 2023 - 2031
10.2.18.5.2.Europe
10.2.18.5.2.1.Market Estimation, 2015 - 2022
10.2.18.5.2.2.Market Forecast, 2023 - 2031
10.2.18.5.3.Asia Pacific
10.2.18.5.3.1.Market Estimation, 2015 - 2022
10.2.18.5.3.2.Market Forecast, 2023 - 2031
10.2.18.5.4.Middle East and Africa
10.2.18.5.4.1.Market Estimation, 2015 - 2022
10.2.18.5.4.2.Market Forecast, 2023 - 2031
10.2.18.5.5.Latin America
10.2.18.5.5.1.Market Estimation, 2015 - 2022
10.2.18.5.5.2.Market Forecast, 2023 - 2031
10.3.Key Segment for Channeling Investments
10.3.1.By Cancer Type
11.Global Particle Therapy Market Analysis and Forecasts, 2023 – 2031
11.1.Overview
11.2.Global Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
11.2.1.Hospitals
11.2.1.1.Definition
11.2.1.2.Market Estimation and Penetration, 2015 - 2022
11.2.1.3.Market Forecast, 2023 - 2031
11.2.1.4.Compound Annual Growth Rate (CAGR)
11.2.1.5.Regional Bifurcation
11.2.1.5.1.North America
11.2.1.5.1.1.Market Estimation, 2015 - 2022
11.2.1.5.1.2.Market Forecast, 2023 - 2031
11.2.1.5.2.Europe
11.2.1.5.2.1.Market Estimation, 2015 - 2022
11.2.1.5.2.2.Market Forecast, 2023 - 2031
11.2.1.5.3.Asia Pacific
11.2.1.5.3.1.Market Estimation, 2015 - 2022
11.2.1.5.3.2.Market Forecast, 2023 - 2031
11.2.1.5.4.Middle East and Africa
11.2.1.5.4.1.Market Estimation, 2015 - 2022
11.2.1.5.4.2.Market Forecast, 2023 - 2031
11.2.1.5.5.Latin America
11.2.1.5.5.1.Market Estimation, 2015 - 2022
11.2.1.5.5.2.Market Forecast, 2023 - 2031
11.2.2.Cancer Treatment Centers
11.2.2.1.Definition
11.2.2.2.Market Estimation and Penetration, 2015 - 2022
11.2.2.3.Market Forecast, 2023 - 2031
11.2.2.4.Compound Annual Growth Rate (CAGR)
11.2.2.5.Regional Bifurcation
11.2.2.5.1.North America
11.2.2.5.1.1.Market Estimation, 2015 - 2022
11.2.2.5.1.2.Market Forecast, 2023 - 2031
11.2.2.5.2.Europe
11.2.2.5.2.1.Market Estimation, 2015 - 2022
11.2.2.5.2.2.Market Forecast, 2023 - 2031
11.2.2.5.3.Asia Pacific
11.2.2.5.3.1.Market Estimation, 2015 - 2022
11.2.2.5.3.2.Market Forecast, 2023 - 2031
11.2.2.5.4.Middle East and Africa
11.2.2.5.4.1.Market Estimation, 2015 - 2022
11.2.2.5.4.2.Market Forecast, 2023 - 2031
11.2.2.5.5.Latin America
11.2.2.5.5.1.Market Estimation, 2015 - 2022
11.2.2.5.5.2.Market Forecast, 2023 - 2031
11.2.3.Research Laboratories
11.2.3.1.Definition
11.2.3.2.Market Estimation and Penetration, 2015 - 2022
11.2.3.3.Market Forecast, 2023 - 2031
11.2.3.4.Compound Annual Growth Rate (CAGR)
11.2.3.5.Regional Bifurcation
11.2.3.5.1.North America
11.2.3.5.1.1.Market Estimation, 2015 - 2022
11.2.3.5.1.2.Market Forecast, 2023 - 2031
11.2.3.5.2.Europe
11.2.3.5.2.1.Market Estimation, 2015 - 2022
11.2.3.5.2.2.Market Forecast, 2023 - 2031
11.2.3.5.3.Asia Pacific
11.2.3.5.3.1.Market Estimation, 2015 - 2022
11.2.3.5.3.2.Market Forecast, 2023 - 2031
11.2.3.5.4.Middle East and Africa
11.2.3.5.4.1.Market Estimation, 2015 - 2022
11.2.3.5.4.2.Market Forecast, 2023 - 2031
11.2.3.5.5.Latin America
11.2.3.5.5.1.Market Estimation, 2015 - 2022
11.2.3.5.5.2.Market Forecast, 2023 - 2031
11.2.4.Others
11.2.4.1.Definition
11.2.4.2.Market Estimation and Penetration, 2015 - 2022
11.2.4.3.Market Forecast, 2023 - 2031
11.2.4.4.Compound Annual Growth Rate (CAGR)
11.2.4.5.Regional Bifurcation
11.2.4.5.1.North America
11.2.4.5.1.1.Market Estimation, 2015 - 2022
11.2.4.5.1.2.Market Forecast, 2023 - 2031
11.2.4.5.2.Europe
11.2.4.5.2.1.Market Estimation, 2015 - 2022
11.2.4.5.2.2.Market Forecast, 2023 - 2031
11.2.4.5.3.Asia Pacific
11.2.4.5.3.1.Market Estimation, 2015 - 2022
11.2.4.5.3.2.Market Forecast, 2023 - 2031
11.2.4.5.4.Middle East and Africa
11.2.4.5.4.1.Market Estimation, 2015 - 2022
11.2.4.5.4.2.Market Forecast, 2023 - 2031
11.2.4.5.5.Latin America
11.2.4.5.5.1.Market Estimation, 2015 - 2022
11.2.4.5.5.2.Market Forecast, 2023 - 2031
11.3.Key Segment for Channeling Investments
11.3.1.By End Users
12.North America Particle Therapy Market Analysis and Forecasts, 2023 – 2031
12.1.Overview
12.1.1.North America Particle Therapy Market Revenue (US$ Mn)
12.2.North America Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
12.2.1.Proton Therapy
12.2.1.1.Single room
12.2.1.2.Multi room
12.2.1.3.Expandable room
12.2.2.Carbon ion Therapy
12.2.2.1.Fixed beam treatment room
12.2.2.2.Rotating gantry treatment room
12.2.3.Hybrid Therapy
12.3.North America Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
12.3.1.Products
12.3.1.1.Cyclotron
12.3.1.2.Synchrotrons
12.3.2.Services
12.4.North America Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
12.4.1.Brain tumors
12.4.2.Spinal cord tumors
12.4.3.Head and neck cancer
12.4.4.Breast cancer
12.4.5.Metastatic tumors
12.4.6.Liver cancer
12.4.7.Pancreatic cancer
12.4.8.Rectal cancer
12.4.9.Gynecological tumors
12.4.10.Bone and Soft tissue tumors
12.4.11.Pediatric cancer
12.4.12.Intraocular tumors
12.4.13.Lung cancer
12.4.14.Esophageal cancer
12.4.15.Kidney cancer
12.4.16.Prostate cancer
12.4.17.Bladder cancer
12.4.18.Others
12.5.North America Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
12.5.1.Hospitals
12.5.2.Cancer Treatment Centers
12.5.3.Research Laboratories
12.5.4.Others
12.6.North America Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Country
12.6.1.U.S
12.6.1.1.U.S Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
12.6.1.1.1.Proton Therapy
12.6.1.1.1.1.Single room
12.6.1.1.1.2.Multi room
12.6.1.1.1.3.Expandable room
12.6.1.1.2.Carbon ion Therapy
12.6.1.1.2.1.Fixed beam treatment room
12.6.1.1.2.2.Rotating gantry treatment room
12.6.1.1.3.Hybrid Therapy
12.6.1.2.U.S Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
12.6.1.2.1.Products
12.6.1.2.1.1.Cyclotron
12.6.1.2.1.2.Synchrotrons
12.6.1.2.2.Services
12.6.1.3.U.S Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
12.6.1.3.1.Brain tumors
12.6.1.3.2.Spinal cord tumors
12.6.1.3.3.Head and neck cancer
12.6.1.3.4.Breast cancer
12.6.1.3.5.Metastatic tumors
12.6.1.3.6.Liver cancer
12.6.1.3.7.Pancreatic cancer
12.6.1.3.8.Rectal cancer
12.6.1.3.9.Gynecological tumors
12.6.1.3.10.Bone and Soft tissue tumors
12.6.1.3.11.Pediatric cancer
12.6.1.3.12.Intraocular tumors
12.6.1.3.13.Lung cancer
12.6.1.3.14.Esophageal cancer
12.6.1.3.15.Kidney cancer
12.6.1.3.16.Prostate cancer
12.6.1.3.17.Bladder cancer
12.6.1.3.18.Others
12.6.1.4.U.S Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.1.4.1.Hospitals
12.6.1.4.2.Cancer Treatment Centers
12.6.1.4.3.Research Laboratories
12.6.1.4.4.Others
12.6.2.Canada
12.6.2.1.Canada Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
12.6.2.1.1.Proton Therapy
12.6.2.1.1.1.Single room
12.6.2.1.1.2.Multi room
12.6.2.1.1.3.Expandable room
12.6.2.1.2.Carbon ion Therapy
12.6.2.1.2.1.Fixed beam treatment room
12.6.2.1.2.2.Rotating gantry treatment room
12.6.2.1.3.Hybrid Therapy
12.6.2.2.Canada Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
12.6.2.2.1.Products
12.6.2.2.1.1.Cyclotron
12.6.2.2.1.2.Synchrotrons
12.6.2.2.2.Services
12.6.2.3.Canada Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
12.6.2.3.1.Brain tumors
12.6.2.3.2.Spinal cord tumors
12.6.2.3.3.Head and neck cancer
12.6.2.3.4.Breast cancer
12.6.2.3.5.Metastatic tumors
12.6.2.3.6.Liver cancer
12.6.2.3.7.Pancreatic cancer
12.6.2.3.8.Rectal cancer
12.6.2.3.9.Gynecological tumors
12.6.2.3.10.Bone and Soft tissue tumors
12.6.2.3.11.Pediatric cancer
12.6.2.3.12.Intraocular tumors
12.6.2.3.13.Lung cancer
12.6.2.3.14.Esophageal cancer
12.6.2.3.15.Kidney cancer
12.6.2.3.16.Prostate cancer
12.6.2.3.17.Bladder cancer
12.6.2.3.18.Others
12.6.2.4.Canada Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.2.4.1.Hospitals
12.6.2.4.2.Cancer Treatment Centers
12.6.2.4.3.Research Laboratories
12.6.2.4.4.Others
12.6.3.Mexico
12.6.3.1.Mexico Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
12.6.3.1.1.Proton Therapy
12.6.3.1.1.1.Single room
12.6.3.1.1.2.Multi room
12.6.3.1.1.3.Expandable room
12.6.3.1.2.Carbon ion Therapy
12.6.3.1.2.1.Fixed beam treatment room
12.6.3.1.2.2.Rotating gantry treatment room
12.6.3.1.3.Hybrid Therapy
12.6.3.2.Mexico Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
12.6.3.2.1.Products
12.6.3.2.1.1.Cyclotron
12.6.3.2.1.2.Synchrotrons
12.6.3.2.2.Services
12.6.3.3.Mexico Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
12.6.3.3.1.Brain tumors
12.6.3.3.2.Spinal cord tumors
12.6.3.3.3.Head and neck cancer
12.6.3.3.4.Breast cancer
12.6.3.3.5.Metastatic tumors
12.6.3.3.6.Liver cancer
12.6.3.3.7.Pancreatic cancer
12.6.3.3.8.Rectal cancer
12.6.3.3.9.Gynecological tumors
12.6.3.3.10.Bone and Soft tissue tumors
12.6.3.3.11.Pediatric cancer
12.6.3.3.12.Intraocular tumors
12.6.3.3.13.Lung cancer
12.6.3.3.14.Esophageal cancer
12.6.3.3.15.Kidney cancer
12.6.3.3.16.Prostate cancer
12.6.3.3.17.Bladder cancer
12.6.3.3.18.Others
12.6.3.4.Mexico Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.3.4.1.Hospitals
12.6.3.4.2.Cancer Treatment Centers
12.6.3.4.3.Research Laboratories
12.6.3.4.4.Others
12.6.4.Rest of North America
12.6.4.1.Rest of North America Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
12.6.4.1.1.Proton Therapy
12.6.4.1.1.1.Single room
12.6.4.1.1.2.Multi room
12.6.4.1.1.3.Expandable room
12.6.4.1.2.Carbon ion Therapy
12.6.4.1.2.1.Fixed beam treatment room
12.6.4.1.2.2.Rotating gantry treatment room
12.6.4.1.3.Hybrid Therapy
12.6.4.2.Rest of North America Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
12.6.4.2.1.Products
12.6.4.2.1.1.Cyclotron
12.6.4.2.1.2.Synchrotrons
12.6.4.2.2.Services
12.6.4.3.Rest of North America Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
12.6.4.3.1.Brain tumors
12.6.4.3.2.Spinal cord tumors
12.6.4.3.3.Head and neck cancer
12.6.4.3.4.Breast cancer
12.6.4.3.5.Metastatic tumors
12.6.4.3.6.Liver cancer
12.6.4.3.7.Pancreatic cancer
12.6.4.3.8.Rectal cancer
12.6.4.3.9.Gynecological tumors
12.6.4.3.10.Bone and Soft tissue tumors
12.6.4.3.11.Pediatric cancer
12.6.4.3.12.Intraocular tumors
12.6.4.3.13.Lung cancer
12.6.4.3.14.Esophageal cancer
12.6.4.3.15.Kidney cancer
12.6.4.3.16.Prostate cancer
12.6.4.3.17.Bladder cancer
12.6.4.3.18.Others
12.6.4.4.Rest of North America Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.4.4.1.Hospitals
12.6.4.4.2.Cancer Treatment Centers
12.6.4.4.3.Research Laboratories
12.6.4.4.4.Others
12.7.Key Segment for Channeling Investments
12.7.1.By Country
12.7.2.By Type
12.7.3.By Offerings
12.7.4.By Cancer Type
12.7.5.By End Users
13.Europe Particle Therapy Market Analysis and Forecasts, 2023 – 2031
13.1.Overview
13.1.1.Europe Particle Therapy Market Revenue (US$ Mn)
13.2.Europe Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
13.2.1.Proton Therapy
13.2.1.1.Single room
13.2.1.2.Multi room
13.2.1.3.Expandable room
13.2.2.Carbon ion Therapy
13.2.2.1.Fixed beam treatment room
13.2.2.2.Rotating gantry treatment room
13.2.3.Hybrid Therapy
13.3.Europe Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
13.3.1.Products
13.3.1.1.Cyclotron
13.3.1.2.Synchrotrons
13.3.2.Services
13.4.Europe Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
13.4.1.Brain tumors
13.4.2.Spinal cord tumors
13.4.3.Head and neck cancer
13.4.4.Breast cancer
13.4.5.Metastatic tumors
13.4.6.Liver cancer
13.4.7.Pancreatic cancer
13.4.8.Rectal cancer
13.4.9.Gynecological tumors
13.4.10.Bone and Soft tissue tumors
13.4.11.Pediatric cancer
13.4.12.Intraocular tumors
13.4.13.Lung cancer
13.4.14.Esophageal cancer
13.4.15.Kidney cancer
13.4.16.Prostate cancer
13.4.17.Bladder cancer
13.4.18.Others
13.5.Europe Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.1.Hospitals
13.5.2.Cancer Treatment Centers
13.5.3.Research Laboratories
13.5.4.Others
13.6.Europe Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Country
13.6.1.France
13.6.1.1.France Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
13.6.1.1.1.Proton Therapy
13.6.1.1.1.1.Single room
13.6.1.1.1.2.Multi room
13.6.1.1.1.3.Expandable room
13.6.1.1.2.Carbon ion Therapy
13.6.1.1.2.1.Fixed beam treatment room
13.6.1.1.2.2.Rotating gantry treatment room
13.6.1.1.3.Hybrid Therapy
13.6.1.2.France Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
13.6.1.2.1.Products
13.6.1.2.1.1.Cyclotron
13.6.1.2.1.2.Synchrotrons
13.6.1.2.2.Services
13.6.1.3.France Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
13.6.1.3.1.Brain tumors
13.6.1.3.2.Spinal cord tumors
13.6.1.3.3.Head and neck cancer
13.6.1.3.4.Breast cancer
13.6.1.3.5.Metastatic tumors
13.6.1.3.6.Liver cancer
13.6.1.3.7.Pancreatic cancer
13.6.1.3.8.Rectal cancer
13.6.1.3.9.Gynecological tumors
13.6.1.3.10.Bone and Soft tissue tumors
13.6.1.3.11.Pediatric cancer
13.6.1.3.12.Intraocular tumors
13.6.1.3.13.Lung cancer
13.6.1.3.14.Esophageal cancer
13.6.1.3.15.Kidney cancer
13.6.1.3.16.Prostate cancer
13.6.1.3.17.Bladder cancer
13.6.1.3.18.Others
13.6.1.4.France Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.1.4.1.Hospitals
13.6.1.4.2.Cancer Treatment Centers
13.6.1.4.3.Research Laboratories
13.6.1.4.4.Others
13.6.2.The UK
13.6.2.1.The UK Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
13.6.2.1.1.Proton Therapy
13.6.2.1.1.1.Single room
13.6.2.1.1.2.Multi room
13.6.2.1.1.3.Expandable room
13.6.2.1.2.Carbon ion Therapy
13.6.2.1.2.1.Fixed beam treatment room
13.6.2.1.2.2.Rotating gantry treatment room
13.6.2.1.3.Hybrid Therapy
13.6.2.2.The UK Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
13.6.2.2.1.Products
13.6.2.2.1.1.Cyclotron
13.6.2.2.1.2.Synchrotrons
13.6.2.2.2.Services
13.6.2.3.The UK Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
13.6.2.3.1.Brain tumors
13.6.2.3.2.Spinal cord tumors
13.6.2.3.3.Head and neck cancer
13.6.2.3.4.Breast cancer
13.6.2.3.5.Metastatic tumors
13.6.2.3.6.Liver cancer
13.6.2.3.7.Pancreatic cancer
13.6.2.3.8.Rectal cancer
13.6.2.3.9.Gynecological tumors
13.6.2.3.10.Bone and Soft tissue tumors
13.6.2.3.11.Pediatric cancer
13.6.2.3.12.Intraocular tumors
13.6.2.3.13.Lung cancer
13.6.2.3.14.Esophageal cancer
13.6.2.3.15.Kidney cancer
13.6.2.3.16.Prostate cancer
13.6.2.3.17.Bladder cancer
13.6.2.3.18.Others
13.6.2.4.The UK Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.2.4.1.Hospitals
13.6.2.4.2.Cancer Treatment Centers
13.6.2.4.3.Research Laboratories
13.6.2.4.4.Others
13.6.3.Spain
13.6.3.1.Spain Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
13.6.3.1.1.Proton Therapy
13.6.3.1.1.1.Single room
13.6.3.1.1.2.Multi room
13.6.3.1.1.3.Expandable room
13.6.3.1.2.Carbon ion Therapy
13.6.3.1.2.1.Fixed beam treatment room
13.6.3.1.2.2.Rotating gantry treatment room
13.6.3.1.3.Hybrid Therapy
13.6.3.2.Spain Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
13.6.3.2.1.Products
13.6.3.2.1.1.Cyclotron
13.6.3.2.1.2.Synchrotrons
13.6.3.2.2.Services
13.6.3.3.Spain Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
13.6.3.3.1.Brain tumors
13.6.3.3.2.Spinal cord tumors
13.6.3.3.3.Head and neck cancer
13.6.3.3.4.Breast cancer
13.6.3.3.5.Metastatic tumors
13.6.3.3.6.Liver cancer
13.6.3.3.7.Pancreatic cancer
13.6.3.3.8.Rectal cancer
13.6.3.3.9.Gynecological tumors
13.6.3.3.10.Bone and Soft tissue tumors
13.6.3.3.11.Pediatric cancer
13.6.3.3.12.Intraocular tumors
13.6.3.3.13.Lung cancer
13.6.3.3.14.Esophageal cancer
13.6.3.3.15.Kidney cancer
13.6.3.3.16.Prostate cancer
13.6.3.3.17.Bladder cancer
13.6.3.3.18.Others
13.6.3.4.Spain Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.3.4.1.Hospitals
13.6.3.4.2.Cancer Treatment Centers
13.6.3.4.3.Research Laboratories
13.6.3.4.4.Others
13.6.4.Germany
13.6.4.1.Germany Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
13.6.4.1.1.Proton Therapy
13.6.4.1.1.1.Single room
13.6.4.1.1.2.Multi room
13.6.4.1.1.3.Expandable room
13.6.4.1.2.Carbon ion Therapy
13.6.4.1.2.1.Fixed beam treatment room
13.6.4.1.2.2.Rotating gantry treatment room
13.6.4.1.3.Hybrid Therapy
13.6.4.2.Germany Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
13.6.4.2.1.Products
13.6.4.2.1.1.Cyclotron
13.6.4.2.1.2.Synchrotrons
13.6.4.2.2.Services
13.6.4.3.Germany Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
13.6.4.3.1.Brain tumors
13.6.4.3.2.Spinal cord tumors
13.6.4.3.3.Head and neck cancer
13.6.4.3.4.Breast cancer
13.6.4.3.5.Metastatic tumors
13.6.4.3.6.Liver cancer
13.6.4.3.7.Pancreatic cancer
13.6.4.3.8.Rectal cancer
13.6.4.3.9.Gynecological tumors
13.6.4.3.10.Bone and Soft tissue tumors
13.6.4.3.11.Pediatric cancer
13.6.4.3.12.Intraocular tumors
13.6.4.3.13.Lung cancer
13.6.4.3.14.Esophageal cancer
13.6.4.3.15.Kidney cancer
13.6.4.3.16.Prostate cancer
13.6.4.3.17.Bladder cancer
13.6.4.3.18.Others
13.6.4.4.Germany Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.4.4.1.Hospitals
13.6.4.4.2.Cancer Treatment Centers
13.6.4.4.3.Research Laboratories
13.6.4.4.4.Others
13.6.5.Italy
13.6.5.1.Italy Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
13.6.5.1.1.Proton Therapy
13.6.5.1.1.1.Single room
13.6.5.1.1.2.Multi room
13.6.5.1.1.3.Expandable room
13.6.5.1.2.Carbon ion Therapy
13.6.5.1.2.1.Fixed beam treatment room
13.6.5.1.2.2.Rotating gantry treatment room
13.6.5.1.3.Hybrid Therapy
13.6.5.2.Italy Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
13.6.5.2.1.Products
13.6.5.2.1.1.Cyclotron
13.6.5.2.1.2.Synchrotrons
13.6.5.2.2.Services
13.6.5.3.Italy Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
13.6.5.3.1.Brain tumors
13.6.5.3.2.Spinal cord tumors
13.6.5.3.3.Head and neck cancer
13.6.5.3.4.Breast cancer
13.6.5.3.5.Metastatic tumors
13.6.5.3.6.Liver cancer
13.6.5.3.7.Pancreatic cancer
13.6.5.3.8.Rectal cancer
13.6.5.3.9.Gynecological tumors
13.6.5.3.10.Bone and Soft tissue tumors
13.6.5.3.11.Pediatric cancer
13.6.5.3.12.Intraocular tumors
13.6.5.3.13.Lung cancer
13.6.5.3.14.Esophageal cancer
13.6.5.3.15.Kidney cancer
13.6.5.3.16.Prostate cancer
13.6.5.3.17.Bladder cancer
13.6.5.3.18.Others
13.6.5.4.Italy Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.5.4.1.Hospitals
13.6.5.4.2.Cancer Treatment Centers
13.6.5.4.3.Research Laboratories
13.6.5.4.4.Others
13.6.6.Nordic Countries
13.6.6.1.Nordic Countries Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
13.6.6.1.1.Proton Therapy
13.6.6.1.1.1.Single room
13.6.6.1.1.2.Multi room
13.6.6.1.1.3.Expandable room
13.6.6.1.2.Carbon ion Therapy
13.6.6.1.2.1.Fixed beam treatment room
13.6.6.1.2.2.Rotating gantry treatment room
13.6.6.1.3.Hybrid Therapy
13.6.6.2.Nordic Countries Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
13.6.6.2.1.Products
13.6.6.2.1.1.Cyclotron
13.6.6.2.1.2.Synchrotrons
13.6.6.2.2.Services
13.6.6.3.Nordic Countries Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
13.6.6.3.1.Brain tumors
13.6.6.3.2.Spinal cord tumors
13.6.6.3.3.Head and neck cancer
13.6.6.3.4.Breast cancer
13.6.6.3.5.Metastatic tumors
13.6.6.3.6.Liver cancer
13.6.6.3.7.Pancreatic cancer
13.6.6.3.8.Rectal cancer
13.6.6.3.9.Gynecological tumors
13.6.6.3.10.Bone and Soft tissue tumors
13.6.6.3.11.Pediatric cancer
13.6.6.3.12.Intraocular tumors
13.6.6.3.13.Lung cancer
13.6.6.3.14.Esophageal cancer
13.6.6.3.15.Kidney cancer
13.6.6.3.16.Prostate cancer
13.6.6.3.17.Bladder cancer
13.6.6.3.18.Others
13.6.6.4.Nordic Countries Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.6.4.1.Hospitals
13.6.6.4.2.Cancer Treatment Centers
13.6.6.4.3.Research Laboratories
13.6.6.4.4.Others
13.6.6.5.Nordic Countries Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Country
13.6.6.5.1.Denmark
13.6.6.5.2.Finland
13.6.6.5.3.Iceland
13.6.6.5.4.Sweden
13.6.6.5.5.Norway
13.6.7.Benelux Union
13.6.7.1.Benelux Union Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
13.6.7.1.1.Proton Therapy
13.6.7.1.1.1.Single room
13.6.7.1.1.2.Multi room
13.6.7.1.1.3.Expandable room
13.6.7.1.2.Carbon ion Therapy
13.6.7.1.2.1.Fixed beam treatment room
13.6.7.1.2.2.Rotating gantry treatment room
13.6.7.1.3.Hybrid Therapy
13.6.7.2.Benelux Union Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
13.6.7.2.1.Products
13.6.7.2.1.1.Cyclotron
13.6.7.2.1.2.Synchrotrons
13.6.7.2.2.Services
13.6.7.3.Benelux Union Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
13.6.7.3.1.Brain tumors
13.6.7.3.2.Spinal cord tumors
13.6.7.3.3.Head and neck cancer
13.6.7.3.4.Breast cancer
13.6.7.3.5.Metastatic tumors
13.6.7.3.6.Liver cancer
13.6.7.3.7.Pancreatic cancer
13.6.7.3.8.Rectal cancer
13.6.7.3.9.Gynecological tumors
13.6.7.3.10.Bone and Soft tissue tumors
13.6.7.3.11.Pediatric cancer
13.6.7.3.12.Intraocular tumors
13.6.7.3.13.Lung cancer
13.6.7.3.14.Esophageal cancer
13.6.7.3.15.Kidney cancer
13.6.7.3.16.Prostate cancer
13.6.7.3.17.Bladder cancer
13.6.7.3.18.Others
13.6.7.4.Benelux Union Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.7.4.1.Hospitals
13.6.7.4.2.Cancer Treatment Centers
13.6.7.4.3.Research Laboratories
13.6.7.4.4.Others
13.6.7.5.Benelux Union Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Country
13.6.7.5.1.Belgium
13.6.7.5.2.The Netherlands
13.6.7.5.3.Luxembourg
13.6.8.Rest of Europe
13.6.8.1.Rest of Europe Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
13.6.8.1.1.Proton Therapy
13.6.8.1.1.1.Single room
13.6.8.1.1.2.Multi room
13.6.8.1.1.3.Expandable room
13.6.8.1.2.Carbon ion Therapy
13.6.8.1.2.1.Fixed beam treatment room
13.6.8.1.2.2.Rotating gantry treatment room
13.6.8.1.3.Hybrid Therapy
13.6.8.2.Rest of Europe Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
13.6.8.2.1.Products
13.6.8.2.1.1.Cyclotron
13.6.8.2.1.2.Synchrotrons
13.6.8.2.2.Services
13.6.8.3.Rest of Europe Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
13.6.8.3.1.Brain tumors
13.6.8.3.2.Spinal cord tumors
13.6.8.3.3.Head and neck cancer
13.6.8.3.4.Breast cancer
13.6.8.3.5.Metastatic tumors
13.6.8.3.6.Liver cancer
13.6.8.3.7.Pancreatic cancer
13.6.8.3.8.Rectal cancer
13.6.8.3.9.Gynecological tumors
13.6.8.3.10.Bone and Soft tissue tumors
13.6.8.3.11.Pediatric cancer
13.6.8.3.12.Intraocular tumors
13.6.8.3.13.Lung cancer
13.6.8.3.14.Esophageal cancer
13.6.8.3.15.Kidney cancer
13.6.8.3.16.Prostate cancer
13.6.8.3.17.Bladder cancer
13.6.8.3.18.Others
13.6.8.4.Rest of Europe Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.8.4.1.Hospitals
13.6.8.4.2.Cancer Treatment Centers
13.6.8.4.3.Research Laboratories
13.6.8.4.4.Others
13.7.Key Segment for Channeling Investments
13.7.1.By Country
13.7.2.By Type
13.7.3.By Offerings
13.7.4.By Cancer Type
13.7.5.By End Users
14.Asia Pacific Particle Therapy Market Analysis and Forecasts, 2023 – 2031
14.1.Overview
14.1.1.Asia Pacific Particle Therapy Market Revenue (US$ Mn)
14.2.Asia Pacific Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
14.2.1.Proton Therapy
14.2.1.1.Single room
14.2.1.2.Multi room
14.2.1.3.Expandable room
14.2.2.Carbon ion Therapy
14.2.2.1.Fixed beam treatment room
14.2.2.2.Rotating gantry treatment room
14.2.3.Hybrid Therapy
14.3.Asia Pacific Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
14.3.1.Products
14.3.1.1.Cyclotron
14.3.1.2.Synchrotrons
14.3.2.Services
14.4.Asia Pacific Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
14.4.1.Brain tumors
14.4.2.Spinal cord tumors
14.4.3.Head and neck cancer
14.4.4.Breast cancer
14.4.5.Metastatic tumors
14.4.6.Liver cancer
14.4.7.Pancreatic cancer
14.4.8.Rectal cancer
14.4.9.Gynecological tumors
14.4.10.Bone and Soft tissue tumors
14.4.11.Pediatric cancer
14.4.12.Intraocular tumors
14.4.13.Lung cancer
14.4.14.Esophageal cancer
14.4.15.Kidney cancer
14.4.16.Prostate cancer
14.4.17.Bladder cancer
14.4.18.Others
14.5.Asia Pacific Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
14.5.1.Hospitals
14.5.2.Cancer Treatment Centers
14.5.3.Research Laboratories
14.5.4.Others
14.6.Asia Pacific Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Country
14.6.1.China
14.6.1.1.China Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
14.6.1.1.1.Proton Therapy
14.6.1.1.1.1.Single room
14.6.1.1.1.2.Multi room
14.6.1.1.1.3.Expandable room
14.6.1.1.2.Carbon ion Therapy
14.6.1.1.2.1.Fixed beam treatment room
14.6.1.1.2.2.Rotating gantry treatment room
14.6.1.1.3.Hybrid Therapy
14.6.1.2.China Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
14.6.1.2.1.Products
14.6.1.2.1.1.Cyclotron
14.6.1.2.1.2.Synchrotrons
14.6.1.2.2.Services
14.6.1.3.China Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
14.6.1.3.1.Brain tumors
14.6.1.3.2.Spinal cord tumors
14.6.1.3.3.Head and neck cancer
14.6.1.3.4.Breast cancer
14.6.1.3.5.Metastatic tumors
14.6.1.3.6.Liver cancer
14.6.1.3.7.Pancreatic cancer
14.6.1.3.8.Rectal cancer
14.6.1.3.9.Gynecological tumors
14.6.1.3.10.Bone and Soft tissue tumors
14.6.1.3.11.Pediatric cancer
14.6.1.3.12.Intraocular tumors
14.6.1.3.13.Lung cancer
14.6.1.3.14.Esophageal cancer
14.6.1.3.15.Kidney cancer
14.6.1.3.16.Prostate cancer
14.6.1.3.17.Bladder cancer
14.6.1.3.18.Others
14.6.1.4.China Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.1.4.1.Hospitals
14.6.1.4.2.Cancer Treatment Centers
14.6.1.4.3.Research Laboratories
14.6.1.4.4.Others
14.6.2.Japan
14.6.2.1.Japan Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
14.6.2.1.1.Proton Therapy
14.6.2.1.1.1.Single room
14.6.2.1.1.2.Multi room
14.6.2.1.1.3.Expandable room
14.6.2.1.2.Carbon ion Therapy
14.6.2.1.2.1.Fixed beam treatment room
14.6.2.1.2.2.Rotating gantry treatment room
14.6.2.1.3.Hybrid Therapy
14.6.2.2.Japan Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
14.6.2.2.1.Products
14.6.2.2.1.1.Cyclotron
14.6.2.2.1.2.Synchrotrons
14.6.2.2.2.Services
14.6.2.3.Japan Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
14.6.2.3.1.Brain tumors
14.6.2.3.2.Spinal cord tumors
14.6.2.3.3.Head and neck cancer
14.6.2.3.4.Breast cancer
14.6.2.3.5.Metastatic tumors
14.6.2.3.6.Liver cancer
14.6.2.3.7.Pancreatic cancer
14.6.2.3.8.Rectal cancer
14.6.2.3.9.Gynecological tumors
14.6.2.3.10.Bone and Soft tissue tumors
14.6.2.3.11.Pediatric cancer
14.6.2.3.12.Intraocular tumors
14.6.2.3.13.Lung cancer
14.6.2.3.14.Esophageal cancer
14.6.2.3.15.Kidney cancer
14.6.2.3.16.Prostate cancer
14.6.2.3.17.Bladder cancer
14.6.2.3.18.Others
14.6.2.4.Japan Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.2.4.1.Hospitals
14.6.2.4.2.Cancer Treatment Centers
14.6.2.4.3.Research Laboratories
14.6.2.4.4.Others
14.6.3.India
14.6.3.1.India Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
14.6.3.1.1.Proton Therapy
14.6.3.1.1.1.Single room
14.6.3.1.1.2.Multi room
14.6.3.1.1.3.Expandable room
14.6.3.1.2.Carbon ion Therapy
14.6.3.1.2.1.Fixed beam treatment room
14.6.3.1.2.2.Rotating gantry treatment room
14.6.3.1.3.Hybrid Therapy
14.6.3.2.India Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
14.6.3.2.1.Products
14.6.3.2.1.1.Cyclotron
14.6.3.2.1.2.Synchrotrons
14.6.3.2.2.Services
14.6.3.3.India Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
14.6.3.3.1.Brain tumors
14.6.3.3.2.Spinal cord tumors
14.6.3.3.3.Head and neck cancer
14.6.3.3.4.Breast cancer
14.6.3.3.5.Metastatic tumors
14.6.3.3.6.Liver cancer
14.6.3.3.7.Pancreatic cancer
14.6.3.3.8.Rectal cancer
14.6.3.3.9.Gynecological tumors
14.6.3.3.10.Bone and Soft tissue tumors
14.6.3.3.11.Pediatric cancer
14.6.3.3.12.Intraocular tumors
14.6.3.3.13.Lung cancer
14.6.3.3.14.Esophageal cancer
14.6.3.3.15.Kidney cancer
14.6.3.3.16.Prostate cancer
14.6.3.3.17.Bladder cancer
14.6.3.3.18.Others
14.6.3.4.India Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.3.4.1.Hospitals
14.6.3.4.2.Cancer Treatment Centers
14.6.3.4.3.Research Laboratories
14.6.3.4.4.Others
14.6.4.New Zealand
14.6.4.1.New Zealand Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
14.6.4.1.1.Proton Therapy
14.6.4.1.1.1.Single room
14.6.4.1.1.2.Multi room
14.6.4.1.1.3.Expandable room
14.6.4.1.2.Carbon ion Therapy
14.6.4.1.2.1.Fixed beam treatment room
14.6.4.1.2.2.Rotating gantry treatment room
14.6.4.1.3.Hybrid Therapy
14.6.4.2.New Zealand Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
14.6.4.2.1.Products
14.6.4.2.1.1.Cyclotron
14.6.4.2.1.2.Synchrotrons
14.6.4.2.2.Services
14.6.4.3.New Zealand Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
14.6.4.3.1.Brain tumors
14.6.4.3.2.Spinal cord tumors
14.6.4.3.3.Head and neck cancer
14.6.4.3.4.Breast cancer
14.6.4.3.5.Metastatic tumors
14.6.4.3.6.Liver cancer
14.6.4.3.7.Pancreatic cancer
14.6.4.3.8.Rectal cancer
14.6.4.3.9.Gynecological tumors
14.6.4.3.10.Bone and Soft tissue tumors
14.6.4.3.11.Pediatric cancer
14.6.4.3.12.Intraocular tumors
14.6.4.3.13.Lung cancer
14.6.4.3.14.Esophageal cancer
14.6.4.3.15.Kidney cancer
14.6.4.3.16.Prostate cancer
14.6.4.3.17.Bladder cancer
14.6.4.3.18.Others
14.6.4.4.New Zealand Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.4.4.1.Hospitals
14.6.4.4.2.Cancer Treatment Centers
14.6.4.4.3.Research Laboratories
14.6.4.4.4.Others
14.6.5.Australia
14.6.5.1.Australia Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
14.6.5.1.1.Proton Therapy
14.6.5.1.1.1.Single room
14.6.5.1.1.2.Multi room
14.6.5.1.1.3.Expandable room
14.6.5.1.2.Carbon ion Therapy
14.6.5.1.2.1.Fixed beam treatment room
14.6.5.1.2.2.Rotating gantry treatment room
14.6.5.1.3.Hybrid Therapy
14.6.5.2.Australia Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
14.6.5.2.1.Products
14.6.5.2.1.1.Cyclotron
14.6.5.2.1.2.Synchrotrons
14.6.5.2.2.Services
14.6.5.3.Australia Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
14.6.5.3.1.Brain tumors
14.6.5.3.2.Spinal cord tumors
14.6.5.3.3.Head and neck cancer
14.6.5.3.4.Breast cancer
14.6.5.3.5.Metastatic tumors
14.6.5.3.6.Liver cancer
14.6.5.3.7.Pancreatic cancer
14.6.5.3.8.Rectal cancer
14.6.5.3.9.Gynecological tumors
14.6.5.3.10.Bone and Soft tissue tumors
14.6.5.3.11.Pediatric cancer
14.6.5.3.12.Intraocular tumors
14.6.5.3.13.Lung cancer
14.6.5.3.14.Esophageal cancer
14.6.5.3.15.Kidney cancer
14.6.5.3.16.Prostate cancer
14.6.5.3.17.Bladder cancer
14.6.5.3.18.Others
14.6.5.4.Australia Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.5.4.1.Hospitals
14.6.5.4.2.Cancer Treatment Centers
14.6.5.4.3.Research Laboratories
14.6.5.4.4.Others
14.6.6.South Korea
14.6.6.1.South Korea Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
14.6.6.1.1.Proton Therapy
14.6.6.1.1.1.Single room
14.6.6.1.1.2.Multi room
14.6.6.1.1.3.Expandable room
14.6.6.1.2.Carbon ion Therapy
14.6.6.1.2.1.Fixed beam treatment room
14.6.6.1.2.2.Rotating gantry treatment room
14.6.6.1.3.Hybrid Therapy
14.6.6.2.South Korea Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
14.6.6.2.1.Products
14.6.6.2.1.1.Cyclotron
14.6.6.2.1.2.Synchrotrons
14.6.6.2.2.Services
14.6.6.3.South Korea Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
14.6.6.3.1.Brain tumors
14.6.6.3.2.Spinal cord tumors
14.6.6.3.3.Head and neck cancer
14.6.6.3.4.Breast cancer
14.6.6.3.5.Metastatic tumors
14.6.6.3.6.Liver cancer
14.6.6.3.7.Pancreatic cancer
14.6.6.3.8.Rectal cancer
14.6.6.3.9.Gynecological tumors
14.6.6.3.10.Bone and Soft tissue tumors
14.6.6.3.11.Pediatric cancer
14.6.6.3.12.Intraocular tumors
14.6.6.3.13.Lung cancer
14.6.6.3.14.Esophageal cancer
14.6.6.3.15.Kidney cancer
14.6.6.3.16.Prostate cancer
14.6.6.3.17.Bladder cancer
14.6.6.3.18.Others
14.6.6.4.South Korea Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.6.4.1.Hospitals
14.6.6.4.2.Cancer Treatment Centers
14.6.6.4.3.Research Laboratories
14.6.6.4.4.Others
14.6.7.Southeast Asia
14.6.7.1.Southeast Asia Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
14.6.7.1.1.Proton Therapy
14.6.7.1.1.1.Single room
14.6.7.1.1.2.Multi room
14.6.7.1.1.3.Expandable room
14.6.7.1.2.Carbon ion Therapy
14.6.7.1.2.1.Fixed beam treatment room
14.6.7.1.2.2.Rotating gantry treatment room
14.6.7.1.3.Hybrid Therapy
14.6.7.2.Southeast Asia Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
14.6.7.2.1.Products
14.6.7.2.1.1.Cyclotron
14.6.7.2.1.2.Synchrotrons
14.6.7.2.2.Services
14.6.7.3.Southeast Asia Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
14.6.7.3.1.Brain tumors
14.6.7.3.2.Spinal cord tumors
14.6.7.3.3.Head and neck cancer
14.6.7.3.4.Breast cancer
14.6.7.3.5.Metastatic tumors
14.6.7.3.6.Liver cancer
14.6.7.3.7.Pancreatic cancer
14.6.7.3.8.Rectal cancer
14.6.7.3.9.Gynecological tumors
14.6.7.3.10.Bone and Soft tissue tumors
14.6.7.3.11.Pediatric cancer
14.6.7.3.12.Intraocular tumors
14.6.7.3.13.Lung cancer
14.6.7.3.14.Esophageal cancer
14.6.7.3.15.Kidney cancer
14.6.7.3.16.Prostate cancer
14.6.7.3.17.Bladder cancer
14.6.7.3.18.Others
14.6.7.4.Southeast Asia Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.7.4.1.Hospitals
14.6.7.4.2.Cancer Treatment Centers
14.6.7.4.3.Research Laboratories
14.6.7.4.4.Others
14.6.7.5.Southeast Asia Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Country
14.6.7.5.1.Indonesia
14.6.7.5.2.Thailand
14.6.7.5.3.Malaysia
14.6.7.5.4.Singapore
14.6.7.5.5.Rest of Southeast Asia
14.6.8.Rest of Asia Pacific
14.6.8.1.Rest of Asia Pacific Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
14.6.8.1.1.Proton Therapy
14.6.8.1.1.1.Single room
14.6.8.1.1.2.Multi room
14.6.8.1.1.3.Expandable room
14.6.8.1.2.Carbon ion Therapy
14.6.8.1.2.1.Fixed beam treatment room
14.6.8.1.2.2.Rotating gantry treatment room
14.6.8.1.3.Hybrid Therapy
14.6.8.2.Rest of Asia Pacific Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
14.6.8.2.1.Products
14.6.8.2.1.1.Cyclotron
14.6.8.2.1.2.Synchrotrons
14.6.8.2.2.Services
14.6.8.3.Rest of Asia Pacific Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
14.6.8.3.1.Brain tumors
14.6.8.3.2.Spinal cord tumors
14.6.8.3.3.Head and neck cancer
14.6.8.3.4.Breast cancer
14.6.8.3.5.Metastatic tumors
14.6.8.3.6.Liver cancer
14.6.8.3.7.Pancreatic cancer
14.6.8.3.8.Rectal cancer
14.6.8.3.9.Gynecological tumors
14.6.8.3.10.Bone and Soft tissue tumors
14.6.8.3.11.Pediatric cancer
14.6.8.3.12.Intraocular tumors
14.6.8.3.13.Lung cancer
14.6.8.3.14.Esophageal cancer
14.6.8.3.15.Kidney cancer
14.6.8.3.16.Prostate cancer
14.6.8.3.17.Bladder cancer
14.6.8.3.18.Others
14.6.8.4.Rest of Asia Pacific Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.8.4.1.Hospitals
14.6.8.4.2.Cancer Treatment Centers
14.6.8.4.3.Research Laboratories
14.6.8.4.4.Others
14.7.Key Segment for Channeling Investments
14.7.1.By Country
14.7.2.By Type
14.7.3.By Offerings
14.7.4.By Cancer Type
14.7.5.By End Users
15.Middle East and Africa Particle Therapy Market Analysis and Forecasts, 2023 – 2031
15.1.Overview
15.1.1.Middle East and Africa Particle Therapy Market Revenue (US$ Mn)
15.2.Middle East and Africa Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
15.2.1.Proton Therapy
15.2.1.1.Single room
15.2.1.2.Multi room
15.2.1.3.Expandable room
15.2.2.Carbon ion Therapy
15.2.2.1.Fixed beam treatment room
15.2.2.2.Rotating gantry treatment room
15.2.3.Hybrid Therapy
15.3.Middle East and Africa Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
15.3.1.Products
15.3.1.1.Cyclotron
15.3.1.2.Synchrotrons
15.3.2.Services
15.4.Middle East and Africa Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
15.4.1.Brain tumors
15.4.2.Spinal cord tumors
15.4.3.Head and neck cancer
15.4.4.Breast cancer
15.4.5.Metastatic tumors
15.4.6.Liver cancer
15.4.7.Pancreatic cancer
15.4.8.Rectal cancer
15.4.9.Gynecological tumors
15.4.10.Bone and Soft tissue tumors
15.4.11.Pediatric cancer
15.4.12.Intraocular tumors
15.4.13.Lung cancer
15.4.14.Esophageal cancer
15.4.15.Kidney cancer
15.4.16.Prostate cancer
15.4.17.Bladder cancer
15.4.18.Others
15.5.Middle East and Africa Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
15.5.1.Hospitals
15.5.2.Cancer Treatment Centers
15.5.3.Research Laboratories
15.5.4.Others
15.6.Middle East and Africa Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Country
15.6.1.Saudi Arabia
15.6.1.1.Saudi Arabia Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
15.6.1.1.1.Proton Therapy
15.6.1.1.1.1.Single room
15.6.1.1.1.2.Multi room
15.6.1.1.1.3.Expandable room
15.6.1.1.2.Carbon ion Therapy
15.6.1.1.2.1.Fixed beam treatment room
15.6.1.1.2.2.Rotating gantry treatment room
15.6.1.1.3.Hybrid Therapy
15.6.1.2.Saudi Arabia Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
15.6.1.2.1.Products
15.6.1.2.1.1.Cyclotron
15.6.1.2.1.2.Synchrotrons
15.6.1.2.2.Services
15.6.1.3.Saudi Arabia Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
15.6.1.3.1.Brain tumors
15.6.1.3.2.Spinal cord tumors
15.6.1.3.3.Head and neck cancer
15.6.1.3.4.Breast cancer
15.6.1.3.5.Metastatic tumors
15.6.1.3.6.Liver cancer
15.6.1.3.7.Pancreatic cancer
15.6.1.3.8.Rectal cancer
15.6.1.3.9.Gynecological tumors
15.6.1.3.10.Bone and Soft tissue tumors
15.6.1.3.11.Pediatric cancer
15.6.1.3.12.Intraocular tumors
15.6.1.3.13.Lung cancer
15.6.1.3.14.Esophageal cancer
15.6.1.3.15.Kidney cancer
15.6.1.3.16.Prostate cancer
15.6.1.3.17.Bladder cancer
15.6.1.3.18.Others
15.6.1.4.Saudi Arabia Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.1.4.1.Hospitals
15.6.1.4.2.Cancer Treatment Centers
15.6.1.4.3.Research Laboratories
15.6.1.4.4.Others
15.6.2.UAE
15.6.2.1.UAE Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
15.6.2.1.1.Proton Therapy
15.6.2.1.1.1.Single room
15.6.2.1.1.2.Multi room
15.6.2.1.1.3.Expandable room
15.6.2.1.2.Carbon ion Therapy
15.6.2.1.2.1.Fixed beam treatment room
15.6.2.1.2.2.Rotating gantry treatment room
15.6.2.1.3.Hybrid Therapy
15.6.2.2.UAE Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
15.6.2.2.1.Products
15.6.2.2.1.1.Cyclotron
15.6.2.2.1.2.Synchrotrons
15.6.2.2.2.Services
15.6.2.3.UAE Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
15.6.2.3.1.Brain tumors
15.6.2.3.2.Spinal cord tumors
15.6.2.3.3.Head and neck cancer
15.6.2.3.4.Breast cancer
15.6.2.3.5.Metastatic tumors
15.6.2.3.6.Liver cancer
15.6.2.3.7.Pancreatic cancer
15.6.2.3.8.Rectal cancer
15.6.2.3.9.Gynecological tumors
15.6.2.3.10.Bone and Soft tissue tumors
15.6.2.3.11.Pediatric cancer
15.6.2.3.12.Intraocular tumors
15.6.2.3.13.Lung cancer
15.6.2.3.14.Esophageal cancer
15.6.2.3.15.Kidney cancer
15.6.2.3.16.Prostate cancer
15.6.2.3.17.Bladder cancer
15.6.2.3.18.Others
15.6.2.4.UAE Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.2.4.1.Hospitals
15.6.2.4.2.Cancer Treatment Centers
15.6.2.4.3.Research Laboratories
15.6.2.4.4.Others
15.6.3.Egypt
15.6.3.1.Egypt Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
15.6.3.1.1.Proton Therapy
15.6.3.1.1.1.Single room
15.6.3.1.1.2.Multi room
15.6.3.1.1.3.Expandable room
15.6.3.1.2.Carbon ion Therapy
15.6.3.1.2.1.Fixed beam treatment room
15.6.3.1.2.2.Rotating gantry treatment room
15.6.3.1.3.Hybrid Therapy
15.6.3.2.Egypt Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
15.6.3.2.1.Products
15.6.3.2.1.1.Cyclotron
15.6.3.2.1.2.Synchrotrons
15.6.3.2.2.Services
15.6.3.3.Egypt Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
15.6.3.3.1.Brain tumors
15.6.3.3.2.Spinal cord tumors
15.6.3.3.3.Head and neck cancer
15.6.3.3.4.Breast cancer
15.6.3.3.5.Metastatic tumors
15.6.3.3.6.Liver cancer
15.6.3.3.7.Pancreatic cancer
15.6.3.3.8.Rectal cancer
15.6.3.3.9.Gynecological tumors
15.6.3.3.10.Bone and Soft tissue tumors
15.6.3.3.11.Pediatric cancer
15.6.3.3.12.Intraocular tumors
15.6.3.3.13.Lung cancer
15.6.3.3.14.Esophageal cancer
15.6.3.3.15.Kidney cancer
15.6.3.3.16.Prostate cancer
15.6.3.3.17.Bladder cancer
15.6.3.3.18.Others
15.6.3.4.Egypt Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.3.4.1.Hospitals
15.6.3.4.2.Cancer Treatment Centers
15.6.3.4.3.Research Laboratories
15.6.3.4.4.Others
15.6.4.Kuwait
15.6.4.1.Kuwait Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
15.6.4.1.1.Proton Therapy
15.6.4.1.1.1.Single room
15.6.4.1.1.2.Multi room
15.6.4.1.1.3.Expandable room
15.6.4.1.2.Carbon ion Therapy
15.6.4.1.2.1.Fixed beam treatment room
15.6.4.1.2.2.Rotating gantry treatment room
15.6.4.1.3.Hybrid Therapy
15.6.4.2.Kuwait Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
15.6.4.2.1.Products
15.6.4.2.1.1.Cyclotron
15.6.4.2.1.2.Synchrotrons
15.6.4.2.2.Services
15.6.4.3.Kuwait Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
15.6.4.3.1.Brain tumors
15.6.4.3.2.Spinal cord tumors
15.6.4.3.3.Head and neck cancer
15.6.4.3.4.Breast cancer
15.6.4.3.5.Metastatic tumors
15.6.4.3.6.Liver cancer
15.6.4.3.7.Pancreatic cancer
15.6.4.3.8.Rectal cancer
15.6.4.3.9.Gynecological tumors
15.6.4.3.10.Bone and Soft tissue tumors
15.6.4.3.11.Pediatric cancer
15.6.4.3.12.Intraocular tumors
15.6.4.3.13.Lung cancer
15.6.4.3.14.Esophageal cancer
15.6.4.3.15.Kidney cancer
15.6.4.3.16.Prostate cancer
15.6.4.3.17.Bladder cancer
15.6.4.3.18.Others
15.6.4.4.Kuwait Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.4.4.1.Hospitals
15.6.4.4.2.Cancer Treatment Centers
15.6.4.4.3.Research Laboratories
15.6.4.4.4.Others
15.6.5.South Africa
15.6.5.1.South Africa Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
15.6.5.1.1.Proton Therapy
15.6.5.1.1.1.Single room
15.6.5.1.1.2.Multi room
15.6.5.1.1.3.Expandable room
15.6.5.1.2.Carbon ion Therapy
15.6.5.1.2.1.Fixed beam treatment room
15.6.5.1.2.2.Rotating gantry treatment room
15.6.5.1.3.Hybrid Therapy
15.6.5.2.South Africa Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
15.6.5.2.1.Products
15.6.5.2.1.1.Cyclotron
15.6.5.2.1.2.Synchrotrons
15.6.5.2.2.Services
15.6.5.3.South Africa Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
15.6.5.3.1.Brain tumors
15.6.5.3.2.Spinal cord tumors
15.6.5.3.3.Head and neck cancer
15.6.5.3.4.Breast cancer
15.6.5.3.5.Metastatic tumors
15.6.5.3.6.Liver cancer
15.6.5.3.7.Pancreatic cancer
15.6.5.3.8.Rectal cancer
15.6.5.3.9.Gynecological tumors
15.6.5.3.10.Bone and Soft tissue tumors
15.6.5.3.11.Pediatric cancer
15.6.5.3.12.Intraocular tumors
15.6.5.3.13.Lung cancer
15.6.5.3.14.Esophageal cancer
15.6.5.3.15.Kidney cancer
15.6.5.3.16.Prostate cancer
15.6.5.3.17.Bladder cancer
15.6.5.3.18.Others
15.6.5.4.South Africa Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.5.4.1.Hospitals
15.6.5.4.2.Cancer Treatment Centers
15.6.5.4.3.Research Laboratories
15.6.5.4.4.Others
15.6.6.Rest of Middle East & Africa
15.6.6.1.Rest of Middle East & Africa Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
15.6.6.1.1.Proton Therapy
15.6.6.1.1.1.Single room
15.6.6.1.1.2.Multi room
15.6.6.1.1.3.Expandable room
15.6.6.1.2.Carbon ion Therapy
15.6.6.1.2.1.Fixed beam treatment room
15.6.6.1.2.2.Rotating gantry treatment room
15.6.6.1.3.Hybrid Therapy
15.6.6.2.Rest of Middle East & Africa Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
15.6.6.2.1.Products
15.6.6.2.1.1.Cyclotron
15.6.6.2.1.2.Synchrotrons
15.6.6.2.2.Services
15.6.6.3.Rest of Middle East & Africa Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
15.6.6.3.1.Brain tumors
15.6.6.3.2.Spinal cord tumors
15.6.6.3.3.Head and neck cancer
15.6.6.3.4.Breast cancer
15.6.6.3.5.Metastatic tumors
15.6.6.3.6.Liver cancer
15.6.6.3.7.Pancreatic cancer
15.6.6.3.8.Rectal cancer
15.6.6.3.9.Gynecological tumors
15.6.6.3.10.Bone and Soft tissue tumors
15.6.6.3.11.Pediatric cancer
15.6.6.3.12.Intraocular tumors
15.6.6.3.13.Lung cancer
15.6.6.3.14.Esophageal cancer
15.6.6.3.15.Kidney cancer
15.6.6.3.16.Prostate cancer
15.6.6.3.17.Bladder cancer
15.6.6.3.18.Others
15.6.6.4.Rest of Middle East & Africa Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.6.4.1.Hospitals
15.6.6.4.2.Cancer Treatment Centers
15.6.6.4.3.Research Laboratories
15.6.6.4.4.Others
15.7.Key Segment for Channeling Investments
15.7.1.By Country
15.7.2.By Type
15.7.3.By Offerings
15.7.4.By Cancer Type
15.7.5.By End Users
16.Latin America Particle Therapy Market Analysis and Forecasts, 2023 – 2031
16.1.Overview
16.1.1.Latin America Particle Therapy Market Revenue (US$ Mn)
16.2.Latin America Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
16.2.1.Proton Therapy
16.2.1.1.Single room
16.2.1.2.Multi room
16.2.1.3.Expandable room
16.2.2.Carbon ion Therapy
16.2.2.1.Fixed beam treatment room
16.2.2.2.Rotating gantry treatment room
16.2.3.Hybrid Therapy
16.3.Latin America Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
16.3.1.Products
16.3.1.1.Cyclotron
16.3.1.2.Synchrotrons
16.3.2.Services
16.4.Latin America Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
16.4.1.Brain tumors
16.4.2.Spinal cord tumors
16.4.3.Head and neck cancer
16.4.4.Breast cancer
16.4.5.Metastatic tumors
16.4.6.Liver cancer
16.4.7.Pancreatic cancer
16.4.8.Rectal cancer
16.4.9.Gynecological tumors
16.4.10.Bone and Soft tissue tumors
16.4.11.Pediatric cancer
16.4.12.Intraocular tumors
16.4.13.Lung cancer
16.4.14.Esophageal cancer
16.4.15.Kidney cancer
16.4.16.Prostate cancer
16.4.17.Bladder cancer
16.4.18.Others
16.5.Latin America Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
16.5.1.Hospitals
16.5.2.Cancer Treatment Centers
16.5.3.Research Laboratories
16.5.4.Others
16.6.Latin America Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Country
16.6.1.Brazil
16.6.1.1.Brazil Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
16.6.1.1.1.Proton Therapy
16.6.1.1.1.1.Single room
16.6.1.1.1.2.Multi room
16.6.1.1.1.3.Expandable room
16.6.1.1.2.Carbon ion Therapy
16.6.1.1.2.1.Fixed beam treatment room
16.6.1.1.2.2.Rotating gantry treatment room
16.6.1.1.3.Hybrid Therapy
16.6.1.2.Brazil Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
16.6.1.2.1.Products
16.6.1.2.1.1.Cyclotron
16.6.1.2.1.2.Synchrotrons
16.6.1.2.2.Services
16.6.1.3.Brazil Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
16.6.1.3.1.Brain tumors
16.6.1.3.2.Spinal cord tumors
16.6.1.3.3.Head and neck cancer
16.6.1.3.4.Breast cancer
16.6.1.3.5.Metastatic tumors
16.6.1.3.6.Liver cancer
16.6.1.3.7.Pancreatic cancer
16.6.1.3.8.Rectal cancer
16.6.1.3.9.Gynecological tumors
16.6.1.3.10.Bone and Soft tissue tumors
16.6.1.3.11.Pediatric cancer
16.6.1.3.12.Intraocular tumors
16.6.1.3.13.Lung cancer
16.6.1.3.14.Esophageal cancer
16.6.1.3.15.Kidney cancer
16.6.1.3.16.Prostate cancer
16.6.1.3.17.Bladder cancer
16.6.1.3.18.Others
16.6.1.4.Brazil Particle Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
16.6.1.4.1.Hospitals
16.6.1.4.2.Cancer Treatment Centers
16.6.1.4.3.Research Laboratories
16.6.1.4.4.Others
16.6.2.Argentina
16.6.2.1.Argentina Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Type
16.6.2.1.1.Proton Therapy
16.6.2.1.1.1.Single room
16.6.2.1.1.2.Multi room
16.6.2.1.1.3.Expandable room
16.6.2.1.2.Carbon ion Therapy
16.6.2.1.2.1.Fixed beam treatment room
16.6.2.1.2.2.Rotating gantry treatment room
16.6.2.1.3.Hybrid Therapy
16.6.2.2.Argentina Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Offerings
16.6.2.2.1.Products
16.6.2.2.1.1.Cyclotron
16.6.2.2.1.2.Synchrotrons
16.6.2.2.2.Services
16.6.2.3.Argentina Particle Therapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
16.6.2.3.1.Brain tumors
16.6.2.3.2.Spinal cord tumors
16.6.2.3.3.Head and neck cancer
16.6.2.3.4.Breast cancer
16.6.2.3.5.Metastatic tumors
16.6.2.3.6.Liver cancer
16.6.2.3.7.Pancreatic cancer
16.6.2.3.8.Rectal cancer
16.6.2.3.9.Gynecological tumors
16.6.2.3.10.Bone and Soft tissue tumors
16.6.2.3.11.Pediatric cancer
16.6.2.3.12.Intraocular tumors